Background
Buprenorphine is a partial mu-agonist approved for use in the maintenance treatment of heroin/opiate addiction. Sublingual formulations of buprenorphine have been extensively introduced in many countries over the last 20 years. Studies have consistently found that buprenorphine maintenance reduces heroin/opiate use, reduces injecting and reduces deaths [1] [2] [3] [4] [5] . Buprenorphine is also used for detoxification [6] .
Current treatments still fail many patients, with approximately 50% of patients dropping out of both buprenorphine and methadone maintenance treatment within 6 months [7] . Failure of opioid substitution treatment (OST) derives partly from poor/non-adherence and diversion of supplies. Supervised dosing is often recommended [8] , but is difficult since standard sublingual buprenorphine can take 5-10 min to dissolve. Extended supervision is also impractical in some situations, for example, busy community pharmacies; treatment in prison. Rapidly dissolving or rapid-dispersal formulations, such as the combination buprenorphine/naloxone film [9, 10] (available in some parts of the world) and the lyophilised tablet (described below) may be beneficial in busy community pharmacies and custodial settings and enable wider prescribing of buprenorphine in these settings.
A further characteristic feature of buprenorphine is the reported much lower respiratory depressant effect. A ceiling effect for respiratory depression with buprenorphine has been described [11] [12] [13] with the respiratory rate staying broadly stable across doses [14] .
We report results from a "first-in-patient" safety trial of a new buprenorphine oral lyophilisate (mono-product) formulation relative to standard sublingual buprenorphine, including scrutiny for any associated respiratory depression and we also present bio-availability data on a consenting subset.
Method

Study Design and Randomisation
A randomised, open-label study was conducted, investigating safety of a new buprenorphine oral lyophilisate wafer (based on Zydis technology [15, 16] ) compared to standard sub-lingual buprenorphine tablets, covering dose induction and maintenance in opioiddependent subjects ( Fig. 1 ) . The study was approved by Brent, London, UK Ethical Committee and registered with EudraCT number: 2012-003560-49. Subjects were randomised (2: 1 ratio) to receive buprenorphine as either the novel buprenorphine oral lyophilisate (approved by regulatory authorities in the UK, Sweden and Malta as Espranor, hereafter "bup-lyo"; n = 23) or standard sub-lingual buprenorphine (Subutex, hereafter "bup-SL"; n = 13), with stratification for regular benzodiazepine use. Sample size was selected after discussion with the UK regulatory authority. Treatment comprised a dose titration period (days 1-7), maintenance period (days [8] [9] [10] [11] [12] [13] [14] , then an extension period (days 15-29) during which "bup-lyo" subjects were switched to "bup-SL" for their ongoing community treatment.
Venous cannulation and collection of blood samples for pharmacokinetic (PK) study were undertaken with a consenting subset of study subjects on day 1 of titration period, days 2 and 7 of maintenance period, and last day of the extension period.
Subjects/Patients
The study cohort comprised 36 opiate-dependent subjects commencing opiate substitution/maintenance treatment with buprenorphine. Eleven subjects consented to, and had adequate venous access for, insertion of indwelling cannula for the supplementary PK study.
Diagnosis and Inclusion/Exclusion Criteria
All subjects were diagnosed to be opiate dependent on the basis of DSM-IV-TR criteria ( Table 1 ) , and were awaiting buprenorphine maintenance treatment (either as new patient, or as scheduled change of treatment). The other inclusion/exclusion criteria ( Table 1 ) deliberately allowed inclusion of subjects with a degree of concurrent use of other drugs (alcohol, cannabis, cocaine), provided this did not constitute the primary diagnosis and did not have a severity that compromised participation in the trial. Similarly, in order to increase real-world applicability and improve generalisability, patients with co-existing physical and mental health disorders (e.g., chronic liver disease, depression) were included, provided severity was not likely to compromise ability to participate in the trial (online suppl. Table 1 ; for all online suppl. material, see www.karger.com/doi/10.1159/000456612).
If subjects had taken either buprenorphine or methadone within 1 day of the scheduled commencement of study treatment, they could enter a pre-randomisation loop, during which buprenorphine and methadone were excluded for at least 1 day and subjects provided with oral morphine if necessary (and then re-considered for the study).
Study Medications and Their Dose Titration
The novel experimental formulation: "bup-lyo" wafer (buprenorphine oral lyophilisate, for which we used Espranor) was administered oro-mucosally (on the tongue), as a freeze-dried, rapidly dispersing wafer form with a porous air-filled structure, for administration without water, and disintegrating rapidly on contact with moisture [15] . Zydis formulations are specifically designed for rapid dispersion on the tongue, as with other orally disintegrating tablets [16] .
The reference formulation: "bup-SL" tablet (standard sub-lingual buprenorphine, for which we used the commercial product Subutex) was administered sublingually with instruction to be retained until disintegration (as per manufacturers' instructions and recommendations for clinical practice).
Dose Titration and Treatment during the Study Period
During the initial dose titration period (days 1-7), buprenorphine dose was an initial 2-4 mg on the first day with an additional 2-4 mg if clinically required, and then increased daily, according to clinical response, up to maximum dose of 24 mg/day ("bup-
Measures
Retention in treatment was measured as the proportion remaining in treatment at (a) end of titration, and (b) end of the maintenance period.
Medication [17] .
Oral disintegration time of "bup-lyo" and "bup-SL" was measured by direct observation, measuring (a) time to disintegration (i.e., tablet could no longer be removed intact) and (b) time until completely dissolved.
Ongoing monitoring included respiratory rate, pulse-oximetry, urine drug screens, plus routine safety assessments including pre/post liver function tests, ECG and pregnancy test. "bup-SL" n = 13 (PK = 3)
Did not receive study medication, n = 2 Reasons: 1 withdrawal of consent 1 lost contact Randomised-received study medication safety and efficacy population, n = 36
Pharmacokinetic population, n = 11 Fig. 1 . Flow diagram of the study. * % Screened, ** % of subjects administered specific study drug. PK, pharmacokinetic study population; DNA, did not attend. Dose induction: following randomisation, subjects were titrated up to a personalised effective single daily dose of the study medication (either "bup-lyo" or "bup-SL"). An effective single daily dose was judged by both patient and clinician to be correct and was assessed through: objective (OOWS) and subjective scoring of severity of opiate withdrawal symptoms (SOWS [25] ), VAS scoring of severity of withdrawal, severity of craving, and adequacy of "hold" from the current prescribed dose.
Titration period (study days 1-7): after subjects had reached their effective dose, they were then observed daily on the same dose for the remainder of this period. Dose adjusted if deemed clinically necessary.
Maintenance period (study days [8] [9] [10] [11] [12] [13] [14] : throughout this period, the dose of study medication was maintained and not altered unless on overriding clinical grounds.
Extension period (study days [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] : during this later stage, all "bup-lyo" randomised subjects were switched to standard sub-lingual buprenorphine ("bup-SL") (either directly or tapered over a period of up to 4 days). For all subjects (i.e., regardless of randomised originally to "bup-lyo" or "bup-SL"), there was an opportunity for further dose adjustment during the extension period.
Pulse-oximetry was monitored continuously for up to 3 h postdose during each titration day (until stable dose) and days 2 and 7 of maintenance period. Subjective (Likert and SOWS) and objective assessments (OOWS) were performed pre-dosing.
Supplementary Study of PKs
Eleven subjects consented to, and had adequate venous access for, cannulation to provide blood samples. These were collected at 0, 5, 10, 15, 30, 60, 120, and 180 min on day 1 of the titration period and days 2 and 7 of the maintenance period, and the last day of the extension period.
Buprenorphine and also the active metabolite norbuprenorphine were assayed by LC-MS-MS (Liquid Chromatography Tandem Mass Spectrometry, Simbec Research Ltd., Merthyr Tydfil, UK), since animal studies identify norbuprenorphine as a potent respiratory depressant [18] [19] [20] [21] .
Statistical Methods
The study sample for analysis was all subjects who received at least one dose of study medication: 23 subjects "bup-lyo," 13 subjects "bup-SL."
To allow for potential differences in treatment group baselines, the 2 treatments during the maintenance phase (days 2 and 7) were compared utilising the change in Likert, SOWS and OOWS scores from baseline (end titration). Similarly, the respiratory safety of the 2 treatments during the maintenance phase was also compared utilising changes in oximetry records from baseline (end titration). These safety assessments included incidents of SpO 2 saturation <90% of ≥ 1 min and total duration of SpO 2 saturation <90% over 0-30 and 0-120 min post-dose. Respiratory safety end points were statistically compared by Wilcoxon rank sum test. Respiratory rates pre-dose and 15, 30, and 60 min postdose were statistically compared by (ANOVA). All tests were performed with Statistical Analysis System (SAS) version 9.3 (SAS Institute Inc., Cary, NC, USA).
Subjects randomised to "bup-lyo" were switched on day 15 to "bup-SL." It was thus possible also to compare the 2 products within-subject; this will be reported separately.
Pharmacokinetics
Buprenorphine and norbuprenorphine C max , T max and AUC 0-3 h were determined separately for buprenorphine and norbuprenorphine utilising Phoenix ® WinNonlin ® version 6.3 software (Pharsight, Princeton, NJ, USA). Data were examined based on the treatment group and dose at each of the 4 PK sampling periods.
Results
Fifty-five subjects were screened, of whom 17 subjects (30.9%) did not meet inclusion/exclusion criteria ( Fig. 1 ) . Two randomised subjects did not receive study treatment (one withdrawing consent, one lost contact). A total of 36 subjects received treatment and comprised the study population; 23 randomised to "bup-lyo," 13 to "bup-SL." Two subjects (one in each group) were regular benzodiazepine users.
Eleven subjects also participated in the PK study (8 "bup-lyo"; 3 "bup-SL"). Two PK subjects (one per group) withdrew during the extension period, and cannulae blockage spoilt PK on a further 2 ("bup-lyo") at final (extension) assessment.
Demographics and Drug Use Histories
The study samples were typical of people presenting for treatment of opiate dependence, although slightly older (mean ± SD 42 ± 8.6, range 23-58 years), mostly white Caucasian (64%) and with a higher proportion male (86%). The age of first opiate use was 25 ± 8.8 (range 11-42 years); the duration of heroin/opiate use prior to the study was 17 ± 11 (range 3-47 years); 50% (18) had ever injected (3 currently; fuller detail in Table 2 ).
Retention and Attrition through Titration and Maintenance Periods
Retention across the 28-day study was 87% (20/23) in "bup-lyo" and 77% (10/13) in "bup-SL" (difference not statistically significant). Retention during the first 14 days (when subjects were randomised to medication) was 96% for "bup-lyo" versus 85% for "bup-SL" at end of titration, and 91 and 85%, respectively, at the end of the maintenance period (differences were not statistically significant; online suppl. appendix Figure A1 ). Thirty (83.3%) subjects completed the entire 28-day study.
Intensity of Withdrawal Symptoms, Craving, and
Adequacy of "Hold" For both medications, moderately high levels of withdrawal severity on day 1 were evident (OOWS and SOWS), then reducing rapidly to low levels within a couple of days, remaining low throughout the remainder of the study period. No significant between-group differences were detected. Online supplementary Figure  2a and b shows OOWS and SOWS over time, and online supplementary Figure 3a -c for intensity of withdrawal, intensity of craving and of adequacy of medication "hold."
The Titration Period Daily doses were individually tailored to clinical response. For "bup-lyo" subjects ( n = 22/23 successfully titrated), the mean ± SD maintenance daily dose was 10.8 ± 4.9 mg, with 3 (14%) on ≤ 4 mg, 6 (27%) on 6-8 mg, 9 (41%) on 10-14 mg, 3 (14%) on 16 mg and 1 (5%) on 20 mg. For "bup-SL" subjects ( n = 11/13 successfully titrated), the mean maintenance daily dose was 9.6 ± 4.3 mg, with 1 subject (9%) on 4 mg, 7 (64%) on 6-8 mg and 3 (27%) on 16 mg.
For both groups, the titration period proceeded smoothly with 18 "bup-lyo" subjects (81.8%) and 10 "bup-SL" subjects (90.9%) reaching their maintenance daily dose by day 3 -online supplementary Figure 4 .
The Maintenance Period
There were no statistically significant differences between "bup-lyo" and "bup-SL" in within-subject changes of either SOWS or OOWS scores from baseline (titration day 7) to either maintenance day 2 or 7, nor with adequacy of "hold," intensity of withdrawal, or intensity of craving. Table 2 . Characteristics of the 2 randomised groups ("bup-lyo" versus "bup-SL"; total population in right-hand column) Lyophilised oral buprenorphine ("bup-lyo"; n = 23), mean (SD), median (range) Sublingual buprenorphine ("bup-SL"; n = 13), mean (SD), median (range) Crossover: Dose Changes Required on Switch from "Bup-Lyo" to "Bup-SL" No dose adjustment was deemed clinically indicated for any of the 20 subjects on "bup-lyo" who switched from "bup-lyo" to "bup-SL" at day 15 (same prescribed dose), and there were no significant differences in subjective and objective scores.
Respiratory Safety and Respiratory Function
There was no statistically significant difference in respiratory depression between "bup-lyo" and "bup-SL" when comparing subject differences from baseline (up to last valid titration oximeter record) to maintenance days 2 and 7 for the number of SpO 2 <90% events lasting ≥ 1 min or for the cumulative duration of SpO 2 <90% in either the 0-30 or 0-120 min post-dose period. There was also no statistically significant difference in respiratory depression between "bup-lyo" and "bup-SL" as determined by the difference in the mean number of SpO 2 <90% events lasting ≥ 1 min in the 0-30 min post-dose period at either maintenance days 2 or 7 ( p = 0.20 and p = 0.19, respectively) from baseline.
Similarly, there was no statistically significant difference between "bup-lyo" and "bup-SL" in the mean difference in total duration of SpO 2 <90% ( p = 0.87 and p = 0.61, respectively) during this period. Mean ± SD durations of SpO 2 <90% in the 0-30 min post-dose period on maintenance days 2 and 7 were 6.1 ± 11.95 and 7.1 ± 13.47 s in the "bup-lyo" group compared to 177.0 ± 544.00 and 14.0 ± 31.25 s in the "bup-SL" group, respectively.
The same conclusions applied to the 0-120 min postdose period assessments, where no statistically significant differences between "bup-lyo" and "bup-SL" were observed for the mean difference in the number of SpO 2 <90% events lasting ≥ 1 min at either maintenance days 2 or 7 ( p = 0.18 and p = 0.19, respectively) and the mean difference in the total duration of SpO 2 <90% ( p = 0.81 and p = 0.29, respectively). Mean ± SD durations of SpO 2 <90% in the 0-120 min post-dose period on maintenance days 2 and 7 were 68.0 ± 92.37 and 61.1 ± 88.94 s in the "bup-lyo" group compared to 499.3 ± 959.26 and 226.0 ± 281.46 s in the "bup-SL" group. There were no statistically significant differences between "bup-lyo" and "bup-SL" for either the mean respiration rate or mean categorical SpO 2 during the 0-60 min post-dose periods across assessment sessions. Numerical values are summarised in Table 3 , and graphically displayed in online supplementary Figures 5a, b.
Adverse Events There were no deaths and no serious adverse events (SAE).
No adverse event (AE) was scored "severe." No treatment-emergent AEs (TEAEs) resulted in withdrawal. However, a greater proportion of "bup-lyo" subjects experienced at least one AE and similarly for TEAE (73.9 and 69.6%, respectively) compared to the "bup-SL" group (30.8 and 15.4%, respectively). These mostly scored "mild," with similar proportions of "moderate" AEs in both treatment groups ("bup-lyo" = 17.4%, "bup-SL" = 23.1%; online suppl. Table 2 ). Moderate TEAEs reported by ≥ 2 subjects included vomiting, arthralgia, hyperhidrosis, and nausea. However, more "bup-lyo" subjects reported a greater number of "mild" TEAEs (48 TEAEs in 17 subjects, 73.9%) versus "bup-SL" subjects (9 TEAEs in 4 subjects, 30.8%). All of these "mild" TEAEs were selflimiting.
The most frequently reported TEAE was headache in the "bup-lyo" group (4 subjects, 17.4%). There were 3 events of oral hypoaesthesia from 2 "bup-lyo" subjects at 5 and 10 min post-administration; these resolved within 20 min, 20-25 min, and "within an hour." One subject also experienced an intermittent itchy feeling at the back of the throat (pruritus). All these events were considered mild but possibly related to study medication. 
Laboratory Test Results, Physical Examination, and ECG Recordings
No clinically significant differences were observed between groups, with findings consistent with expectations for this patient population.
A majority of subjects in both treatment groups had at least one positive report from drug testing for cocaine ("bup-lyo" = 52.2%, "bup-SL" = 76.9%) during titration and/or maintenance.
Disintegration and Solubility of the "Bup-Lyo" and "Bup-SL" Tablets
At dosing occasions, a record was made of both time to disintegration (i.e., tablet could no longer be removed intact) and time to complete disintegration (see Fig. 2 ). Over all periods, 96.3% of "bup-lyo" administrations achieved partial disintegration on the tongue in ≤ 15 vs. 71.8% with "bup-SL" ( p < 0.001). At 2 min, "bup-lyo" had completely dissolved in 58.0% of administrations versus only 5.1% ("bup-SL"; p < 0.0001). The median time for tablets to completely disintegrate was 2.0 min for "buplyo" versus 10 min for "bup-SL" ( p < 0.0001).
All assessments of buccal mucosa during administration were reported as normal.
PKs (from Volunteer Subsample) -Buprenorphine and nor-Buprenorphine
Blood samples that could be analysed for PK were available from 11 subjects (8 "bup-lyo" and 3 "bup-SL"), yielding 21 sessions over days 2 and 7 of the maintenance period (15 "bup-lyo", 6 "bup-SL").
Since subjects were on individualised maintenance doses, we examined PK curves for a dose-adjusted 4 mg dose. Samples were collected on days 2 and 7 of the maintenance period ( Fig. 3 ) . In summary, these dose-normalised data find comparability in norbuprenorphine PK profiles between "bup-lyo and "bup-SL" despite apparent increased bioavailability for "bup-lyo" for buprenorphine concentrations. (We will report on this and on the relationship to respiratory function in a future publication).
Of particular PK interest were the 5 subjects for whom PK data were available following administration of both "bup-lyo" and "bup-SL". These subjects received the same dose of "bup-lyo" on maintenance day 7 as bup-SL at extension end (all had received repeat dosing for 13-15 days) and provide within subject relative bioavailability. For these subjects, "bup-lyo" demonstrated a higher mean (SD) buprenorphine bioavailability (Cmax: 185.8 ± 88.2% and AUC0-3 h: 169.8 ± 62.0%) relative to bup-SL. However, for norbuprenorphine the mean (SD) bioavailability was comparable (Cmax: 109.6 ± 42.2% and AUC0-3 h: 105.0 ± 39.4%) relative to bup-SL.
Discussion
Very few clinical problems were encountered with the new buprenorphine oral lyophilisate wafer. The investigation only examined the early stages of treatment and the outpatient study was coordinated from a structured research facility: nevertheless, from a clinical standpoint, its use was found to be very similar to use of standard sublingual buprenorphine during both induction or maintenance, with personalised maintenance dose achieved within 3 days for most patients, and equal retention rates across the 2 groups. Very similar scores were obtained on measures of adequacy of drug effect and with scores of withdrawal severity and craving. Furthermore, from the point of view of clinical management (and despite increased bioavailability subsequently identified), no dosage adjustment was necessary on switch-over from "buplyo" to "bup-SL."
There was remarkably rapid disintegration of the lyophilisate tablets ("bup-lyo"), with complete disintegration by 3 min for more than 75% of "bup-lyo" administrations versus less than 25% of "bup-SL" administrations. A serendipitous clinical observation was that, during dosing on the first days, some anxious patients had very dry mouths resulting in slower disintegration. This rapid disintegration and consequent greater ease of supervised dosing may increase the feasibility of buprenorphine treatment in busy community and custodial settings when supervised dosing is still considered important. This now needs to be explored clinically. No SAEs occurred, although there was higher reporting of (not serious) AEs. Higher buprenorphine plasma levels with "bup-lyo" might have contributed to this greater reporting rate although open-label randomisation might also contribute to reports regarding a novel buprenorphine formulation. The active medication is the same in both formulations and thus this seems the likely explanation, although further study and pharmacovigilance are recommended.
A key purpose of the study was to investigate safety and, in particular, whether the increased bioavailability (observed by the manufacturer from prior healthy volunteer study, unpublished) might create any excess respiratory depressant effect. Across the trial, indices of respiratory depression remained minimal for both medications (continuous SpO 2 readings from finger pulseoximetry, plus observation of respiratory rate), with no significant differences observed between the 2 medications on direct comparison. We are also conducting further exploratory analyses of the relationships between indices of respiratory depression and plasma levels of buprenorphine and nor-buprenorphine (on which we will report later).
The findings from the subsidiary PK study are interesting, although the small sample size means that the investigation needs confirmation with proper powered sample size. The good availability of buprenorphine with the new lyophilised buprenorphine ("bup-lyo") means that, compared with "bup-SL," there is a substantial overall increase in the bioavailability of buprenorphine. The duration of action was similar. The low bio-availability of buprenorphine in "bup-SL" has been reported previously, with approximately half the bioavailability when compared with the original buprenorphine liquid [22, 23] . The combination buprenorphine/naloxone tablets ("Suboxone") was found to have 20% increased bioavailability versus "bup-SL" [24] , and a new generic buprenorphine/ naloxone had approximately 40% increased bioavailability to Suboxone [25] (hence presumably even more bioavailable versus "bup-SL"). Furthermore, some countries have a large proportion of patients receiving buprenorphine doses below recommended maintenance doses [26] : will the introduction of a formulation with better bio-availability result in either lower dose or alternatively higher effective dosing?
This increased bioavailability will presumably have implications for drug dosing. In regular clinical practice, dose titration is personalised and subsequent dose adjustments are based on individualised assessment of patient response. However, if there is ever a need or a decision to switch patients between formulations, there will also be need for guidance on dose adjustments to achieve equivalent effective dose. It is unclear how much this matters, since, in this study, no clinical need to increase dose was identified when switching from "bup-lyo" to "bup-SL." In their Cochrane review, Mattick et al. [1] raised the possibility that the different drug effect from buprenorphine (compared with methadone) may account, at least in part, for the repeatedly observed lower retention rates with buprenorphine (versus methadone) [2] [3] [4] [5] 7] . There is a possibility, to be explored in future clinical trials, that the more rapid absorption of the new generation of tablets and wafers might produce an earlier perceived drug effect and, potentially, better retention rates with the new formulations of buprenorphine.
We find no increased bioavailability (in fact slightly lower plasma levels) of the metabolite norbuprenorphine, despite the increased bioavailability of buprenorphine itself. This is potentially interesting as norbuprenorphine is a more potent respiratory depressant (compared with buprenorphine itself). Indeed buprenorphine is, in animal studies at least, actually protective against the respiratory depressant effect of norbuprenorphine [27] . Will high plasma buprenorphine levels in conjunction with low norbuprenorphine levels be the desired relationship? We are conducting separate exploratory analyses of this aspect.
Limitations of the study need consideration. Although randomised, the study was open-label, and hence there is potential for bias in either direction -either concern about the new formulation, or alternatively a belief of greater effect. The study was of modest sample size and also used a standard between-subject design and hence subjects were not identical. (We subsequently switched "bup-lyo" patients back to standard sublingual buprenorphine for continued treatment outside the trial on which we will report separately). PK analyses were conducted on very small sample sizes and PK data needed to be dosenormalised to enable meaningful comparison because each patient was dose-titrated to a personalised maintenance dose.
Two final considerations were arrived at. The "buplyo" lyophilised tablet is a mono-product. This is in sharp contrast to the combination buprenorphine/naloxone tablets more recently developed. Does it matter that it is without naloxone? For supervised dosing, there is no benefit from the inclusion of naloxone (if the supervised medication cannot be removed and concealed) although for unsupervised dosing, the situation will require separate consideration.
Finally, is the development of a new "rapidly disintegrating" oral formulation of buprenorphine worth the effort? It would seem successful to address the major concern of concealment and later abuse associated with forms of buprenorphine with slow disintegration -this advantage would be expected to be similar for other recent rapid-dispersal buprenorphine formulations [28] . Hopefully, these rapid-dissolving variants of buprenorphine may increase the range of settings in which buprenorphine maintenance can safely be delivered, such as settings where it is unrealistic to expect full supervision of dosing over several minutes, for example, busy community pharmacies and, especially, OST in the prison context (where average time per patient dosing is less than a minute per patient). These will be contexts which warrant particular attention in future studies.
